GEXVal Completes Additional Funding of JPY 110 Million in Series C Extension Round

―To Accelerate Development in Australia and Expand the Pipeline―

株式会社GEXVal
2024年6月25日 

GEXVal Completes Additional Funding of JPY 110 Million in Series C Extension Round
―To Accelerate Development in Australia and Expand the Pipeline―

GEXVal Inc. (President & CEO Juran Kato; Location: Fujisawa, Kanagawa, Japan), a drug discovery venture focusing on rare* and untreatable diseases, has secured an additional JPY 110 million through a third-party allotment of new shares, as part of Series C Round** conducted in 2023. This extension round included investments from Mizuho Capital Co., Ltd. and other reputable and emerging leaders in the pharmaceutical sector.

The purpose of the Series C Round is to accelerate the development program based on the milestone achievement of Phase I trials conducted in Australia.  By adding a new indication, we aim to increase the value of our drug candidate and expand its business opportunities, thereby delivering innovative medicine to broader patient population.

With the additional funding, the cumulative total for the Series C Round now stands at JPY 565 million. Other investors participating in this round include Axil Capital, UTC Investment Co., Ltd. (Seoul, South Korea), Oita Venture Capital Co., Ltd., alongside existing investors Mitsubishi UFJ Capital Co., Ltd., and SMBC Venture Capital Co., Ltd.

References：
*Rare disease: Definition varies between countries.
- Japan (<50,000、<4 in 10,000, with population of 128 Million)
-- MHLW  https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html
-- Japan Intractable Disease Information Center  https://www.nanbyou.or.jp/ 
- US   (<200,000、<6.37 in 10,000 with population of 1400 Million)
-- NORD  https://rarediseases.org/about/
- EU   (<250,000、<5 in 10,000 with population of 514 Million)
-- Orphanet  https://www.orpha.net/consor/cgi-bin/index.php

**：News release on the financing conducted in 2023　
https://gexval.com/en/ir-en/gexval-completed-the-close-of-new-funding-round-with-jpy-450-million-usd-3-million/

 

 

有关本事宜请咨询:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com

 

End of document.